A new screening tool for early recognition of ATTRv polyneuropathy in clinical practice: AmyloScan<sup>®</sup>.

Step 2 Although some items of step 1 did not reach statistical significance, they were nevertheless included in step 2 as some differences might have been lost due to the low number of patients (PD-Q items pain (i.e., burning) and tingling), imprecisely formulated questions (family history), and significance in the clinical examination but not the anamnesis (muscle atrophy and gait impairment).

also in 111,027 other papers